Navigation Links
Data Presented At Breast Cancer Symposium 2014 Validates Biscayne Pharmaceuticals' GHRH Target In Breast Cancer
Date:9/3/2014

SAN FRANCISCO and MIAMI BEACH, Fla., Sept. 3, 2014 /PRNewswire/ -- Biscayne Pharmaceuticals, Inc., today announced that data supporting the anti-cancer potential of its growth hormone-releasing hormone (GHRH) technology will be featured in a presentation at the American Society of Clinical Oncology's (ASCO) Breast Cancer Symposium 2014. The data will be presented by Biscayne's Medical Director, Norman Block, MD, who is also Clinical Director of the Endocrine, Polypeptide and Cancer Institute at the Veterans Affairs Medical Center in Miami and the L. Austin Weeks Family Professor of Urologic Research at the University of Miami Miller School of Medicine.

Scientists have long known that GHRH, which is made in the brain, releases growth hormone to manage growth and tissue repair in nearby cells. Dr. Andrew V. Schally, a world-renowned drug researcher and Nobel laureate, discovered that other cells throughout the body, including cancer cells, also have receptors for GHRH. Cancer cells contain GHRH receptors and also produce the GHRH hormone, thereby fueling their own growth. Biscayne Pharmaceuticals has licensed rights to Dr. Schally's GHRH discoveries and is developing GHRH antagonists that inhibit tumor growth by binding to and blocking the activity of the GHRH receptors on cancer cells.

Much of the earlier work on GHRH and cancer has been conducted in preclinical models. In the Breast Cancer Symposium 2014 poster presentation1, Dr. Block and his colleagues present data on GHRH using specimens from breast cancer patients. They conclude that the majority of breast cancers, including both primary and metastatic tumors, are GHRH-receptor positive, confirming the validity of GHRH as a potential therapeutic target for new breast
'/>"/>

SOURCE Biscayne Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
2. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
3. Startling results in synthetic chemistry presented in Nature Chemistry
4. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
5. New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
6. Top Contenders For the First Annual 2012 Fright Night Awards Presented By Cancer Bites Announced
7. Promising Data Presented on GenVec Malaria Program
8. Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
9. Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
10. Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
11. Data on the Selexis SUREtechnology Platform to be Presented at PEPTALK 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... ATCC, the premier global biological materials ... important appointments to the senior leadership team. Barbie Bigelow ... and Technology and Dr. Maryellen de Mars also joins ... Both roles are new positions at ATCC. ... at ATCC described the additions as part of a ...
(Date:9/23/2014)...  Age Defying Dermatology ® , owned and operated ... of the first clinics in the Bay Area to ... tattoo removal. The treatment safely and effectively erases tattoos ... removal has been a lengthy, painful, and all too ... opportunity to erase tattoo pigment more efficiently with far ...
(Date:9/23/2014)... 2014   GenoSpace , a precision medicine software ... to enable the broad use of genomic data in ... been awarded Phase I of a Fast Track Small ... of Health (NIH) to enable enhanced data access and ... http://photos.prnewswire.com/prnh/20140922/147649 During the past decade, ...
(Date:9/23/2014)... 2014 Healthcare professionals, patients ... convene at the Society for Integrative Oncology ... October 26-28 in Houston, Texas to discuss ... in individualized integrative cancer care. This multi-disciplinary ... nutritionists, naturopaths, acupuncturists, and other complementary care ...
Breaking Biology Technology:ATCC Announces New Appointments to its Leadership Team 2ATCC Announces New Appointments to its Leadership Team 3Age Defy Now Offers World's Most Advanced Technology for Tattoo Removal 2GenoSpace Awarded Fast Track SBIR Grant to Enable Data Access and Cohort Construction for Biorepositories 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 3
... and Webcast on November 9 at 8:00 a.m. ... Halozyme Therapeutics, Inc.,(Nasdaq: HALO ), a biopharmaceutical ... matrix, today reported financial,results for the three and ... unique capabilities in navigating the complexities of the,extracellular ...
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today reported financial ... Net loss for the quarter and nine months ended ... per share and $0.46 per share,compared to a net loss ... share, in the same periods last year. Revenues were ...
... 8 Inverness Medical,Innovations, Inc. (Amex: IMA ), ... market and other conditions, 7,000,000 shares of its common,stock ... public offering. Certain selling stockholders of the Company,are also ... stock in the,offering. The Company expects to grant the ...
Cached Biology Technology:Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 2Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 3Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 4Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 5Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 6Kosan Announces Third Quarter 2007 Financial Results 2Kosan Announces Third Quarter 2007 Financial Results 3Kosan Announces Third Quarter 2007 Financial Results 4Kosan Announces Third Quarter 2007 Financial Results 5Kosan Announces Third Quarter 2007 Financial Results 6Kosan Announces Third Quarter 2007 Financial Results 7Inverness Medical Innovations Announces Proposed Public Offering of Common Stock 2Inverness Medical Innovations Announces Proposed Public Offering of Common Stock 3
(Date:9/23/2014)... Pattern formation is essential in the development of animals ... how can genetic information be translated in a reliable ... , The French-flag model of stripe formation is ... by the different colours of the French flag, is ... i.e. at high, middle or low concentrations of the ...
(Date:9/23/2014)... 23 de septiembre de 2014 ... 1290 Infinity II LC, el nuevo instrumento ... su portafolio de cromatografía líquida. El sistema ... de laboratorio que alcancen nuevos niveles de ... uso y capacidad de integración de laboratorio. ...
(Date:9/22/2014)... Researchers at the University of Chicago have shown that ... (ICU) only a handful of pathogenic microbe species remain ... pathogens and discovered that some can become deadly when ... to illness. , The findings, published in mBio ... for Microbiology, may lead to better monitoring and treatment ...
Breaking Biology News(10 mins):Recreating the stripe patterns found in animals by engineering synthetic gene networks 2Agilent Technologies anuncia el lanzamiento del Sistema 1290 Infinity II LC 2Agilent Technologies anuncia el lanzamiento del Sistema 1290 Infinity II LC 3Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 3
... best-studied single-celled organisms around, is a master of industrial efficiency. ... just one product: itself. It exists to make copies of ... the lowest possible cost, with the greatest possible efficiency. ... by the energy and resources it uses to maintain its ...
... facial structure of an ancient relative of modern humans ... hard nuts and seeds as part of a survival ... team of researchers that includes Florida State University,s Dennis ... Proceedings of the National Academy of Science, ...
... gearing up to return to Russia to oversee preparations for ... launch on 16 March 2009. This follows implementation of the ... delayed the launch of GOCE by Eurockot Launch Services last ... at the Plesetsk Cosmodrome in northern Russia to arrange logistical ...
Cached Biology News:Bacteria are models of efficiency 2March launch planned for ESA's gravity mission 2
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
IHC Select Anti-p53, prediluted,wild & mutant, a.a. 19-26, clone DO-7 Immunogen: Human p53 Available Date: 37775...
Feline Rhinotracheitis Virus...
Biology Products: